pyrroles has been researched along with nb 598 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, S; Hiyoshi, H; Ikuta, H; Ito, M; Kurusu, N; Okada, T; Saeki, T; Shinmyo, D; Tanaka, H; Tanaka, K; Yanagimachi, M; Yasuda, N; Yoshida, I | 1 |
| Boerner, JL; Bohin, N; Ge, Y; Irwin, ME; Mueller, KL | 1 |
2 other study(ies) available for pyrroles and nb 598
| Article | Year |
|---|---|
Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes.
Topics: Animals; Atorvastatin; Benzylamines; Cells, Cultured; Cholesterol; Enzyme Inhibitors; Farnesol; Farnesyl-Diphosphate Farnesyltransferase; Hepatocytes; Heptanoic Acids; Lipid Metabolism; Male; Oxidation-Reduction; Pyrroles; Rats; Rats, Sprague-Dawley; Thiophenes; Triglycerides | 2003 |
Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Atorvastatin; Benzylamines; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heptanoic Acids; Humans; Lovastatin; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Thiophenes | 2011 |